Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313118

— · B

9dd09d5c-44c5-57de-81b3-8f22dea8c2c9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MTORC1_SIGNALING+0.400
  • ANGIOGENESIS+0.390
  • E2F_TARGETS+0.390
  • G2M_CHECKPOINT+0.380
  • HEDGEHOG_SIGNALING+0.380
  • MYC_TARGETS_V1+0.380
  • MYC_TARGETS_V2+0.370
  • PANCREAS_BETA_CELLS+0.360
  • ESTROGEN_RESPONSE_EARLY+0.340
  • UNFOLDED_PROTEIN_RESPONSE+0.340

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.540
  • INTERFERON_GAMMA_RESPONSE-0.490
  • ALLOGRAFT_REJECTION-0.470
  • IL6_JAK_STAT3_SIGNALING-0.440
  • INFLAMMATORY_RESPONSE-0.260
  • TNFA_SIGNALING_VIA_NFKB-0.210
  • COMPLEMENT-0.170
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
  • IL2_STAT5_SIGNALING-0.120
  • KRAS_SIGNALING_UP-0.120

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-85-6798-01A-11R-1949-07
lung-landscapes@6
—cohortSQ20.841
2SRR35579803
breast-umap@18
—E0.840
3SRR8518158
breast-umap@18
—E0.838
4TCGA-22-5482-01A-01R-1635-07
lung-landscapes@6
—cohortSQ20.835
5SRR8518411
breast-umap@18
—E0.830
620020076.Her2HRpos
breast-umap@18
—C0.830
7TCGA-92-7341-01A-31R-2045-07
lung-landscapes@6
—cohortSQ20.829
8TCGA-C4-A0F7-01A-11R-A084-07
bladder-landscape@3
——0.824
9TCGA-A2-A04R-01A-41R-A109-07
breast-umap@18
—B0.823
10TCGA-21-5786-01A-01R-1635-07
lung-landscapes@6
—cohortSQ10.822

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MTORC1_SIGNALING0.400Inavolisib— uncovered
ANGIOGENESIS0.390Remibrutinib— uncovered
E2F_TARGETS0.390Inavolisib— uncovered
G2M_CHECKPOINT0.380Inavolisib— uncovered
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
MYC_TARGETS_V10.380Inavolisib— uncovered
MYC_TARGETS_V20.370Idelalisib— uncovered
PANCREAS_BETA_CELLS0.360Cobimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.340Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.340Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.290Idelalisib— uncovered
TGF_BETA_SIGNALING0.250Inavolisib— uncovered
APICAL_JUNCTION0.220Inavolisib— uncovered
GLYCOLYSIS0.220Inavolisib— uncovered
ANDROGEN_RESPONSE0.210Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.210Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.200Remibrutinib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
UV_RESPONSE_UP0.180Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.180Inavolisib— uncovered